Johnson & Johnson ( JNJ ) is a true Dividend King with more than 60 years of consecutive dividend growth. In this uncertain market, investing in a dividend juggernaut with above-inflation long-term growth is just the medicineI have been an investor for a number of years mainly focusing on dividend paying companies. I think dividends and, perhaps more importantly, the growth of them, are foundational for high risk-adjusted long term returns. My approach is therefore to focus on stocks that either pay stable ...

The Dow Jones Industrial Average (^DJI) was up 305.43 (+0.66%) points today, closing at 46,429.49. Dow Futures (YM=F) also signaled strength, rising 280.00 (+0.60%) points to reach 46,695.00. The primary driver for Wednesday’s market action was a better-than-expected Durable Goods report, which suggested that capital spending remains resilient despite elevated borrowing costs. This economic data sparked a rally in cyclical stocks, as investors gained confidence in a "soft landing" scenario for the U.S. econ ...

Turning 65 with $1 million saved puts you in a position most Americans will likely never reach, but hitting this number is only half the work. The more important question is what that $1 million actually produces every month for the next 25 to 30 years, and whether that income will keep pace with a life that keeps getting more expensive. Quick Read A $1 million portfolio at 65 generates $2,917 to $5,833 monthly depending on yield strategy, with conservative 3-4% yields producing roughly $2,917, balance ...

Key TakeawaysThe U.S. has delivered a 15-point ceasefire proposal to Iran via Pakistani officials, including provisions for sanctions relief, a nuclear rollback, and guaranteed access to the Strait of Hormuz.BlackRock (BLK) CEO Larry Fink warned that a spike in oil prices to $150 per barrel would trigger a global recession, as energy costs continue to pressure European economies.European equity markets rallied on hopes of a diplomatic breakthrough, with Germany’s DAX rising 1.5% and the STOXX 600 gaining 0. ...

Key Takeaways JNJ stock stayed above 50- and 200-day SMAs for 8 months, signaling sustained bullish momentum.J&'s growth is driven by Innovative Medicine strength, new drugs, and R&D and M&A spend.JNJ faces Stelara patent loss, China headwinds, and 74,000 talc lawsuits, impacting future outlook.Johnson & Johnson’s (JNJ) stock has remained firmly above its 50-day and 200-day simple moving averages (SMAs) for more than eight months, dating back to mid-July 2025, reflecting sustained investor confidence. Notab ...

Quick Read iShares U.S. Pharmaceuticals ETF (IHE) has 46.8% of its $1.1B portfolio concentrated in Johnson & Johnson (JNJ), up 14% year-to-date on strong DARZALEX sales of $3.90B, and Eli Lilly (LLY), down 15% year-to-date despite Mounjaro hitting $7.41B in Q4 2025 revenue. The fund itself is flat year-to-date, down 0.5%, reflecting opposing performance between its two dominant holdings facing pricing pressure and manufacturing constraints. The Trump administration’s aggressive drug pricing reform thro ...

Last Wednesday , Johnson & Johnson ( JNJ ) announced that the FDA had approved Icotyde, a once-daily oral peptide for the treatment of plaque psoriasis. This drug selectively blocks the interleukin-23 receptor (IL-23) and was a joint discovery withBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employm ...

Last Wednesday , Johnson & Johnson ( JNJ ) announced that the FDA had approved Icotyde, a once-daily oral peptide for the treatment of plaque psoriasis. This drug selectively blocks the interleukin-23 receptor (IL-23) and was a joint discovery withBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employm ...

Johnson & Johnson (NYSE:JNJ) ranks among the best most active stocks to buy right now. On March 13, Johnson & Johnson (NYSE:JNJ) revealed results from a Phase 1 study of an innovative intravesical drug-releasing mechanism with erdafitinib (Erda-iDRS) in patients with non-muscle-invasive bladder cancer who had specific fibroblast growth factor receptor mutations. Pixabay/Public Domain According to the company, the trial met its major safety goals. The intermediate-risk sample of 62 patients had an 89% co ...

Core Insights - TuHURA Biosciences has appointed Dr. Craig L. Tendler as the leader of its VISTA Program in AML and other blood-related cancers, while he continues his role on the Board of Directors [1][2] - Dr. Tendler brings over 29 years of experience in drug development, having coordinated over 30 oncology regulatory approvals and 15 new medical entity approvals, contributing to more than $16 billion in global sales from multiple myeloma treatments [1][2] - The company is focused on developing TBS-2025, a VISTA inhibiting antibody, which is expected to address immunosuppressive roles in AML, particularly in NPM1 mutated cases [2][6] Company Overview - TuHURA Biosciences, Inc. is a Phase 3 immuno-oncology company that develops novel therapeutics aimed at overcoming resistance to cancer immunotherapy [4] - The company’s lead product, IFx-2.0, is designed to counter primary resistance to checkpoint inhibitors and is currently undergoing a Phase 3 trial in combination with Keytruda® for advanced Merkel Cell Carcinoma [5] - TuHURA acquired TBS-2025 through a merger with Kineta Inc. and is advancing it into Phase 2 development for mutNPM1 r/r AML [6] Leadership and Experience - Dr. Tendler previously served as Vice President of Oncology Clinical Development at Johnson & Johnson, where he was instrumental in securing global approvals for several oncology treatments [2][3] - His experience includes leading clinical diligence teams for significant acquisitions and co-development agreements in the oncology sector [2][3] - Dr. Tendler has also held academic positions and has been involved in various cancer research initiatives, enhancing his expertise in the field [3]